ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer

This ASCENT-03 Phase 3 study compared sacituzumab govitecan with chemotherapy in patients with previously untreated advanced TNBC who are ineligible for PD-L1 inhibitors, demonstrating potential efficacy and safety in this challenging population. Read More ›

Wrap-Up

First Clinical Data of DB-1305/BNT325 (TROP2 ADC) in Pretreated TNBC: Phase 1/2 Efficacy and Safety Insights

This phase 1/2 trial presents the first clinical data on DB-1305/BNT325, a TROP2-targeting antibody–drug conjugate, demonstrating efficacy and safety in patients with pretreated triple-negative breast cancer. Read More ›

Wrap-Up

Patient-Reported Outcomes in ASCENT-04/KEYNOTE-D19: Sacituzumab Govitecan + Pembrolizumab vs Chemotherapy + Pembrolizumab in PD-L1–positive Metastatic Triple-Negative Breast Cancer

ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer

The phase 3 ASCENT-04/KEYNOTE-D19 trial evaluated patient-reported outcomes comparing sacituzumab govitecan plus pembrolizumab with chemotherapy plus pembrolizumab in previously untreated PD-L1–positive metastatic TNBC, offering insights into quality of life and symptom management. Read More ›

Wrap-Up

Low-Dose Pembrolizumab With Anthracycline and Taxane in Triple-Negative Breast Cancer: Results From a Randomized Controlled Trial

ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer

This trial evaluated the addition of low-dose pembrolizumab to neoadjuvant anthracycline and taxane regimens, revealing potential synergy in triple-negative breast cancer. Read More ›

Wrap-Up

Novel MUC1-C ADC Demonstrates Potent Antitumor Activity in Triple-Negative Breast Cancer

ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer

This study highlights the remarkable antitumor potency of a novel MUC1-C ADC, offering a promising therapeutic option for patients with triple-negative breast cancer. Read More ›

Triple-Negative Breast Cancer Coverage Brought to You By

ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer